Therapeutic Asset Ratings

266 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Golidocitinib Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Golidocitinib Large Granular Lymphocyte Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Golidocitinib Mycosis Fungoides	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Golidocitinib NK-LGL Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Golidocitinib Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Herombopag Thrombocytopenia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Inotuzumab Ozogamicin Precursor Lymphoblastic Lymphoma/Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Linperlisib Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Mitoxantrone Epigenetic Repression	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Mitoxantrone Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Obinutuzumab Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Olverembatinib Adult Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Omacetaxine CEBPA Double Mutation	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
PREDNISONE TABLETS Epigenetic Repression	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Tucidinostat Allogeneic Hematopoietic Cell Transplantation (HCT)	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Tucidinostat Epigenetic Repression	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Venetoclax Disease Characteristic	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Venetoclax Precursor Lymphoblastic Lymphoma/Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Vinorelbine Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Zanubrutinib Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Bcma-Cart Cells Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (52)
Promethazine DLBCL	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (52)
Anti-Bcma Car-T Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (51)
Isatuximab Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (51)
Selinexor Chronic Myelomonocytic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (51)

Showing 126 to 150 of 266 assets

PreviousPage 6 of 11Next